secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibrx Biosciences, Inc. (INBX)
CIK:        0002007919
Form:       8-K
Filed at:   2026-09-08T20:01:51+00:00
Accession:  0002007919-26-000047
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibrx INBRX-106 nearly doubles cORR in Phase 2 HNSCC; PFS 9.6 vs 4.9 months
-----------------------------------------------------------------------------

- cORR 48.3% (INBRX-106+pembro) vs 26.5% (pembro alone); CR 13.8% vs 0%.
- Median PFS 9.6 vs 4.9 months; 6-mo PFS 72.4% vs 42.8%.
- HPV+ subgroup: cORR 80% vs 33.3%, CR 30% vs 0%, PFS6 90% vs 33%.
- Plans to expand Phase 2 by ~50 HPV+ OPSCC patients; Phase 3 as confirmatory.
- Combination manageable; common AEs rash, fatigue, diarrhea (low grade).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2007919/000200791926000047/0002007919-26-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2007919/000200791926000047/inhibrx-20260908.htm
  HTML page:      https://secwatch.observer/filing/0002007919-26-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer